<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04285788</url>
  </required_header>
  <id_info>
    <org_study_id>AdVance</org_study_id>
    <nct_id>NCT04285788</nct_id>
  </id_info>
  <brief_title>Incidence and Outcomes Associated With the Management of Adenovirus Infections in Allogenic Hematopoietic Cell Transplant Recipients</brief_title>
  <acronym>AdVance</acronym>
  <official_title>Incidence and Outcomes Associated With the Management of Adenovirus Infections in Allogeneic Hematopoietic Cell Transplant Recipients: AdVance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chimerix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chimerix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To depict the incidence, outcomes and standards of care (SoC) of adenovirus (AdV) infections
      and associated practice patterns in allogeneic hematopoietic cell transplant recipients. It
      is expected that participating centers will be in the UK, France, Spain, Germany and Italy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To assess non-relapse related mortality 3 and 6 months after first AdV Virema in paediatric allo-HCT recipients</measure>
    <time_frame>3 and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the number of hospitalizations</measure>
    <time_frame>3-6 months</time_frame>
    <description>Assess for both legnth of stay and ICU stays and length of stays</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the rate of progression of Adv infection</measure>
    <time_frame>3-6 months</time_frame>
    <description>rate of progression to disseminated AdV disease within the first year following allo-HCT</description>
  </secondary_outcome>
  <enrollment type="Actual">216</enrollment>
  <condition>Adenovirus Infections, Human</condition>
  <eligibility>
    <study_pop>
      <textblock>
        compromised of all allo-HCT recipients at participating centers during the pre-specified
        study period
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least one AdV positive test, regardless of specimen within 6 months following the
             first allo-HCT

          -  Subjects first allo-HCT must have been performed between 1 January 2013 and 30
             September 2015

        Exclusion Criteria:

          -  AdV negative
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 24, 2020</study_first_submitted>
  <study_first_submitted_qc>February 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2020</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Adenoviridae Infections</mesh_term>
    <mesh_term>Adenovirus Infections, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

